madman
Super Moderator
Shalin Shah explains how testosterone serves as a key biomarker for overall health and outlines common symptoms that indicate testing is needed: including fatigue, muscle loss, and decreased libido. He emphasizes that while lifestyle factors like diet, sleep, and exercise are foundational, hormone replacement should be considered as a complementary treatment approach, particularly given the environmental factors contributing to declining testosterone levels in men. The conversation also covers the need for personalized treatment approaches and the importance of maintaining physiologic levels rather than seeking super-physiologic dosages.
Shalin Shah shares his personal experience of being tested for testosterone at age 30 after becoming a father, which led him to establish a decade-long focus on testosterone health. He explains that testosterone serves as an important biomarker for overall health, affecting cardiovascular health, glucose metabolism, insulin sensitivity, bone health, and muscle health.Key takeaways
Highlights
- Testosterone is one of the most important biomarkers for overall health, providing insights into cardiovascular health, glucose metabolism, bone health, muscle health, and inflammation
- The TRAVERSE study released in June 2023 definitively proved that testosterone replacement therapy does not cause heart attacks, debunking earlier flawed studies
- Approximately 25 million men in the U.S. are hypogonadal, but only 2-3 million are currently on therapy; the goal is to reach 10-12 million for better population health outcomes
- Oral testosterone therapy represents a breakthrough, bypassing the liver through lymphatic absorption and providing daily physiologic levels versus the roller coaster effect of weekly injections
- Testing should be standard practice regardless of symptoms, as testosterone deficiency can manifest differently in different individuals
- Patients must be their own advocates, as many traditional physicians lack education on hormone replacement therapy
Shalin Shah is a distinguished leader in the field of metabolic health, specializing in testosterone replacement therapy. As the Chief Executive Officer of Marius Pharmaceuticals, he was instrumental in the development and FDA approval of KYZATREX® (testosterone undecanoate) CIII Capsules, an oral testosterone treatment for adult men with low or no testosterone levels due to certain medical conditions.
Shalin has become one of the most trusted voices in the testosterone and hormone health space. Spearheading a national education effort through his nonprofit, The Testosterone Project, he hopes to improve the public's understanding of hormone health among both patients and physicians. Most recently, he presented to the U.S. Food and Drug Administration, advocating for modernized testosterone regulations to expand responsible access for patients and empower doctors to better treat hormone deficiencies.
